Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells
Journal
Pharmacology
Journal Volume
106
Journal Issue
44259
Pages
154-168
Date Issued
2021
Author(s)
Abstract
Introduction: Xeroderma pigmentosum complementation group C (XPC) protein is an important DNA damage recognition factor involved in nucleotide excision repair and regulation of non-small-cell lung cancer (NSCLC) cell proliferation and viability. 17-Allyla
SDGs
Other Subjects
bevacizumab; protein kinase B; tanespimycin; xeroderma pigmentosum group C protein; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; angiogenesis inhibitor; antineoplastic agent; benzoquinone derivative; bevacizumab; chromone derivative; DNA binding prot
Publisher
S. Karger AG
Type
journal article